Updates
Peptide news, distilled.
Scientific readouts, FDA actions, social-media trends, and seller quality changes worth your attention. No hot takes, no sponsored content.
RegulatoryApril 25, 2026
What the FDA's tightening on compounded GLP-1s means for you
As supply chains stabilize and regulatory eyes sharpen, the rules of the road for compounding semaglutide and tirzepatide are changing.
ScienceApril 22, 2026
Retatrutide — what the trial data does (and doesn't) tell us
A new generation of "Triple G" peptides is producing numbers that have left the scientific community stunned. Here's what to actually take from the data.
SourcingApril 18, 2026
Why third-party testing matters more than "pharma grade" marketing
In the world of peptide research, the most dangerous phrase you can encounter isn't "experimental"—it's "just trust us."